Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides

Biochemical Pharmacology

Volumn 51, Issue 4, 1996, Pages 461-469

  Stewart, Alistair J ^a,c   Canitrot, Yvan ^a   Baracchini, Edgardo ^b   Dean, Nicholas M ^b   Deely, Roger G ^a   Cole, Susan P C ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b ISIS PHARMACEUTICALS   (United States)

^c CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

Author keywords

antisense; chemotherapy; MRP; multidrug resistance; RNase H

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 7592; ISIS 7593; ISIS 7594; ISIS 7595; ISIS 7597; ISIS 7598; ISIS 7599; ISIS 7600; ISIS 7601; ISIS 7602; ISIS 7603; ISIS 7604; ISIS 7605; ISIS 7606; ISIS 7607; ISIS 7608; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL;

EID: 0030071190     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02220-1     Document Type: Article

References (60)

1. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
2. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC and Deeley RG, Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994.
3. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EGE, Baas F and Borst P, Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750, 1993.
4. Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH and Twentyman PR, A 190-kilodalton protein overexpression in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86: 110-117, 1994.
5. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG and Cole SPC, Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 53: 3221-3225, 1993.
6. Krishnamachary N and Center MS, The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 53: 3658-3661, 1993.
7. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC and Sehested M, Sequential coexpression of the multidrug resistance genes MRP and mdrl and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55: 459-462, 1995.
8. Schneider E, Horton JK, Yang C-H, Nakagawa M and Cowan KH, Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152-158, 1994.
9. Slapak CA, Fracasso PM, Martell RL, Toppmeyer DL, Lecerf J-M and Levy SB, Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug resistant murine erythroleukemia cells. Cancer Res 54: 5607-5613, 1994.
10. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SPC and Kuwano M, Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71: 907-913, 1995.
11. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM and Deeley RG, Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994.
12. Roninson IB, From amplification to function: The case of the MDR1 gene. Mutat Res 276: 151-161, 1992.
13. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
14. Chin K-V, Pastan I and Gottesman MM, Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60: 157-180, 1993.
15. Endicott JA and Ling V, The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
16. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S and Sakurai Y, Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43: 2905-2910, 1983.
17. Ford JM and Hait WN, Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1991.
18. Georges E, Sharom FJ and Ling V, Multidrug resistance and chemosensitization: Therapeutic implications for cancer chemotherapy. Adv Pharmacol 21: 185-220, 1990.
19. Cole SPC, Downes HF and Slovak ML, Effect of calcium antagonists on the chemosensitivity of two multidrug resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer 59: 42-46, 1989.
20. Barrand MA, Rhodes T, Center MS and Twentyman PR, Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 29: 408-415, 1993.
21. Gollapudi S and Gupta S, Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A. Anticancer Res 12: 2127-2132, 1992.
22. Corrias MV and Tonini GP, An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res 12: 1431-1438, 1992.
23. Quattrone A, Papucci L, Morganti M, Coronnello M, Mini E, Mazzei T, Colonna FP, Garbesi A and Capaccioli S, Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol Res 6: 311-320, 1994.
24. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T and Parmiani G, Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 46: 727-732, 1990.
25. Vasanthakumar G and Ahmed NK, Modulation of drug resistance in a daunorubicin resistant subline with oligonucleotide methylphosphonates. Cancer Commun 1: 225-232, 1989.
26. Kiehntopf M, Brach MA, Licht T, Petschauer S, Karawajew L, Kirschning C and Herrmann F, Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 13: 4645-4652, 1994.
27. Bertram J, Paifner K, Killian M, Brysch W, Schlingensiepen K-H, Hiddemann W and Kneba M, Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anticancer Drugs 6: 124-134, 1995.
28. Thierry AR, Rahman A and Dritschilo A, Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 190: 952-960, 1993.
29. Chiang MY, Chan H, Zounes MA, Freier SM and Bennett CF, Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266: 18162-18171, 1991.
30. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF and Freier SM, Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 267: 19954-19962, 1992.
31. Mirski SEL, Gerlach JH and Cole SPC, Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47: 2694-2598, 1987.
32. Cole SPC and Deeley RG, Multidrug resistance-associated protein: Sequence correction. Science 260: 879, 1993.
33. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SPC and Deeley RG, Characterization of the 190 kDa multidrug resistance protein (MRP) is drug-selected and transfected human tumor cells. Cancer Res 55: 102-110, 1995.
34. Mirski SEL and Cole SPC, Antigens associated with multidrug resistance in H69AR, a small cell lung cancer cell line. Cancer Res 49: 5719-5724, 1989.
35. Cole SPC, Pinkoski MJ, Bhardwaj G and Deeley RG, Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 65: 498-502, 1992.
36. r 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54: 5788-5792, 1994.
37. Mirski SEL and Cole SPC, Multidrug resistance-associated antigens on drug-sensitive and -resistant human tumour cell lines. Br J Cancer 64: 15-22, 1991.
38. Inoue H, Hayase Y, Iwai S and Ohtsuka E, Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNAase H. FEBS Lett 215: 327-330, 1987.
39. Cole SPC, Downes HF, Mirski SEL and Clements DJ, Alterations in glutathione and glutathione-related enzymes in a multidrug resistant small cell lung cancer cell line. Mol Pharmacol 37: 192-197, 1990.
40. Evans CD, Mirski SEL, Danks MK and Cole SPC, Reduced levels of topoisomerase IIα and IIβ in a multidrug-resistant lung-cancer cell line. Cancer Chemother Pharmacol 34: 242-248, 1994.
41. Cole SPC, The 1991 Merck Frosst Award. Multidrug resistance in small cell lung cancer. Can J Physiol Pharmacol 70: 313-329, 1992.
42. Jedlitschky G, Leier I, Buchholz U, Center M and Keppler D, ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54: 4833-4836, 1994.
43. 4 and structurally related conjugates. J Biol Chem 269: 27807-27810, 1994.
44. Wagner RW, Gene inhibition using antisense oligodeoxynucleotides. Nature 372: 333-335, 1994.
45. Nakamura H, Oda Y, Iwai S, Inoue H, Ohtsuka E, Kanaya S, Kimura S, Katsuda C, Katayanagi K, Morikawa K, Miyashiro H and Ikehara M, How does RNase H recognize a DNA-RNA hybrid? Proc Natl Acad Sci USA 88: 11535-11539, 1991.
46. Crooke ST, Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32: 329-376, 1992.
47. Helene C and Toulme JJ, Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049: 99-125, 1990.
48. Cohen JS, Phosphorothioate oligodeoxynucleotides. In: Antisense Research and Applications (Eds. Crooke ST and Lebleu B), pp. 205-221. CRC Press, New York, 1993.
49. Agrawal S and Tang JY, An antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev 2: 261-266, 1992.
50. Stein CA, Anti-sense oligodeoxynucleotides - Promises and pitfalls. Leukemia 6: 967-974, 1992.
51. Marcus-Sekura CJ, Techniques for using antisense oligodeoxyribonucleotides to study gene expression. Analyt Biochem 172: 289-295, 1988.
52. Saison-Behmoaras T, Tocqué B, Rey I, Chassignol M, Thuong NT and Hélène C, Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J 10: 1111-1118, 1991.
53. Monia BP, Lesnik EA, Gonzalez C, Lima WF and Freier SM, Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268: 14514-14522, 1993.
54. Giles RV, Spiller DG and Tidd DM, Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligonucleotides. Antisense Res Dev 5: 23-31, 1995.
55. Dean NM, McKay R, Condon TP and Bennett CF, Inhibition of protein kinase Cα expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM1) mRNA by phorbol esters. J Biol Chem 269: 16416-16424, 1994.
56. Bennett CF, Chiang MY, Chan H, Shoemaker JE and Mirabelli CK, Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41: 1023-1033, 1992.
57. Mirabelli CK and Crooke ST, Antisense oligonucleotides in the context of modern molecular drug discovery and development. In: Antisense Research and Applications (Eds. Crooke ST and Lebleu B), pp. 7-35. CRC Press, New York, 1993.
58. Crooke RM, In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des 6: 609-646, 1991.
59. Jaroszewski JW, Kaplan O, Syi J-L, Sehested M, Faustino PJ and Cohen JS, Concerning antisense inhibition of the multiple drug resistance gene. Cancer Commun 2: 287-294, 1990.
60. Dean NM and McKay R, Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91: 11762-11766, 1994.